Rafferty Asset Management
LCTX icon

Rafferty Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Rafferty Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-193,756
Closed -$488K – 1314
2021
Q3 		$488K Buy
+193,756
New +$497K ﹤0.01% 1048

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rafferty Asset Management's LCTX Position: Q4 2021 in Review

Rafferty Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 193,756 shares — an estimated $488K sold.

Rafferty Asset Management first reported a position in LCTX in Q3 2021 and held it in 1 quarter. The position peaked at $488K in Q3 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • Rafferty Asset Management reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 193,756 Lineage Cell Therapeutics shares in Q4 2021, an estimated $488K.
  • Rafferty Asset Management first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 1 quarter.
  • Rafferty Asset Management's Lineage Cell Therapeutics position peaked at $488K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.